Verastem Inc (VSTM)

$3.85 -0.36 (-8.55%)
Market Cap 373.47M
Revenue (ttm) 30.91M
Net Income (ttm) -209.47M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -677.68%
Debt to Equity Ratio 0.89
Volume 2,975,300
Avg Vol 2,377,912
Day's Range N/A - N/A
Shares Out 87.87M
Stochastic %K 24%
Beta 0.27
Analysts Strong Sell
Price Target $16.00

Company Profile

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small mole...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 292 4200
Address:
117 Kendrick Street, Suite 500, Needham, United States
Always_neutral
Always_neutral Jun. 24 at 11:22 PM
$VSTM My brokerage recently sending any vstm order through a representative. This happened to few other stocks in the past and unfortunately they were in midst of an offering. I called them this morning. The rep just said they was a flag post on.this ticker but he doesn't know why. Anyway, my experience with this kind of situation always end up being an offering. Two recent examples were ANVS and ATOM. Anyway, it could be nothing but be careful with your bets. Sharing for FYI only. I will be glad if it helps someone. Good luck.
3 · Reply
Marketismanipulated2
Marketismanipulated2 Jun. 24 at 10:39 PM
$VSTM please announce a fucking buyout soon!
1 · Reply
ians
ians Jun. 24 at 10:25 PM
$VSTM There's the combo (VS-7375 + pan-RAS molecular glue) that could prevent tumor immune escape. 👍 Let's see early combo POC data ☘️💎 "Verastem and Erasca announce their intent to evaluate VS-7375 in combination with ERAS-0015, Erasca’s investigational pan-RAS molecular glue, in advanced KRAS G12D-mutant solid tumors" https://finance.yahoo.com/healthcare/articles/vs-7375-demonstrates-clinical-activity-200100930.html
1 · Reply
SagehenNed
SagehenNed Jun. 24 at 8:22 PM
$VSTM While the science may be decent, Dan and his executive team have created no value for shareholders. His financial management has been abysmal and the BOD has been asleep at the switch. It’s past time for an activist group to take over.
0 · Reply
sweddle
sweddle Jun. 24 at 8:20 PM
$VSTM
1 · Reply
Icabod63
Icabod63 Jun. 24 at 7:56 PM
$VSTM I am still bullish! Shame on me! My gut tells me an offering is coming in the $3.50 to $3.75 range and it has been leaked.
2 · Reply
Marketismanipulated2
Marketismanipulated2 Jun. 24 at 7:54 PM
$VSTM I don't remember hearing any bad news in that report, what the fuck am I missing? Corrupt motherfuckers!
0 · Reply
Crivit
Crivit Jun. 24 at 7:51 PM
$VSTM Clearly pure manipulation and preparation for a buyout.
1 · Reply
UnlikelyResult
UnlikelyResult Jun. 24 at 7:15 PM
$VSTM Down 7% in two hours on fewer than 100,000 shares. Not exactly a rush to the exits. But a great oppprtunity to fan panic by some
0 · Reply
Marketismanipulated2
Marketismanipulated2 Jun. 24 at 7:09 PM
$VSTM who the fuck would STILL be selling at these prices?
0 · Reply
Latest News on VSTM
Verastem Transcript: Study update

Jun 23, 2026, 4:30 PM EDT - 1 day ago

Verastem Transcript: Study update

Verastem Press release: Study update

Jun 23, 2026, 4:30 PM EDT - 1 day ago

Verastem Press release: Study update

Verastem Slides: Study update

Jun 23, 2026, 4:30 PM EDT - 1 day ago

Verastem Slides: Study update

Verastem reports ‘positive’ preliminary data from ongoing TARGET-D trial

2026-06-23T20:08:14.000Z - 1 day ago

Verastem reports ‘positive’ preliminary data from ongoing TARGET-D trial

VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors

Jun 23, 2026, 4:01 PM EDT - 1 day ago

VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors

VS

Verastem price target lowered to $8 from $15 at Jefferies

2026-06-23T17:03:54.000Z - 1 day ago

Verastem price target lowered to $8 from $15 at Jefferies

Verastem announces safety, efficacy results from RAMP 205 Phase 1b/2a study

2026-06-17T11:36:43.000Z - 7 days ago

Verastem announces safety, efficacy results from RAMP 205 Phase 1b/2a study

Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in First-Line Metastatic Pancreatic Cancer

Jun 17, 2026, 7:30 AM EDT - 7 days ago

Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in First-Line Metastatic Pancreatic Cancer

Verastem doses first Patient in TARGET-D 201 Phase 2 trial of VS-7375

2026-06-16T20:07:47.000Z - 8 days ago

Verastem doses first Patient in TARGET-D 201 Phase 2 trial of VS-7375

Verastem Oncology Doses First Patient in TARGET-D 201 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Pancreatic Cancer

Jun 16, 2026, 4:01 PM EDT - 8 days ago

Verastem Oncology Doses First Patient in TARGET-D 201 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Pancreatic Cancer

Verastem Oncology to Host Investor Conference Call and Report Updated Data and Progress Across VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor TARGET-D Clinical Program

Jun 15, 2026, 4:01 PM EDT - 9 days ago

Verastem Oncology to Host Investor Conference Call and Report Updated Data and Progress Across VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor TARGET-D Clinical Program

Verastem up 11% at $4.00 after announcing FDA Fast Track designation for VS-7375

2026-06-03T20:23:19.000Z - 21 days ago

Verastem up 11% at $4.00 after announcing FDA Fast Track designation for VS-7375

Verastem announces FDA Fast Track designation for VS-7375

2026-06-03T20:06:01.000Z - 21 days ago

Verastem announces FDA Fast Track designation for VS-7375

Verastem Oncology Announces U.S. FDA Fast Track Designation for VS-7375, an Oral and Potential Best-in-Class Investigational KRAS G12D (ON/OFF) Inhibitor for the Treatment of KRAS G12D-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Jun 3, 2026, 4:01 PM EDT - 21 days ago

Verastem Oncology Announces U.S. FDA Fast Track Designation for VS-7375, an Oral and Potential Best-in-Class Investigational KRAS G12D (ON/OFF) Inhibitor for the Treatment of KRAS G12D-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Verastem Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 9:20 AM EDT - 21 days ago

Verastem Transcript: Jefferies Global Healthcare Conference 2026

Verastem Oncology to Present at Jefferies Healthcare Conference

May 27, 2026, 7:30 AM EDT - 4 weeks ago

Verastem Oncology to Present at Jefferies Healthcare Conference

Verastem appoints Michael Bailey to board of directors

2026-05-26T12:54:22.000Z - 4 weeks ago

Verastem appoints Michael Bailey to board of directors

Verastem Oncology Appoints Michael P. Bailey to its Board of Directors

May 26, 2026, 7:30 AM EDT - 4 weeks ago

Verastem Oncology Appoints Michael P. Bailey to its Board of Directors

Verastem Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 20, 2026, 9:30 AM EDT - 5 weeks ago

Verastem Transcript: RBC Capital Markets Global Healthcare Conference 2026

Verastem Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

May 19, 2026, 4:00 PM EDT - 5 weeks ago

Verastem Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

Verastem price target lowered to $14 from $16 at Mizuho

2026-05-14T12:35:05.000Z - 5 weeks ago

Verastem price target lowered to $14 from $16 at Mizuho

Verastem Oncology to Present at Upcoming Investor Conferences

May 12, 2026, 7:30 AM EDT - 6 weeks ago

Verastem Oncology to Present at Upcoming Investor Conferences

Verastem price target lowered to $18 from $19 at BTIG

2026-05-08T12:55:59.000Z - 6 weeks ago

Verastem price target lowered to $18 from $19 at BTIG

On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian Cancer

May 8, 2026, 7:30 AM EDT - 6 weeks ago

On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian Cancer

Verastem price target raised to $18 from $16 at Alliance Global

2026-05-08T11:20:06.000Z - 6 weeks ago

Verastem price target raised to $18 from $16 at Alliance Global

Verastem reports Q1 adjusted EPS (43c), consensus (47c)

2026-05-07T21:47:04.000Z - 6 weeks ago

Verastem reports Q1 adjusted EPS (43c), consensus (47c)

Verastem Earnings Call Transcript: Q1 2026

May 7, 2026, 4:30 PM EDT - 6 weeks ago

Verastem Earnings Call Transcript: Q1 2026

Verastem Earnings release: Q1 2026

May 7, 2026, 4:30 PM EDT - 6 weeks ago

Verastem Earnings release: Q1 2026

Verastem Quarterly report: Q1 2026

May 7, 2026, 4:30 PM EDT - 6 weeks ago

Verastem Quarterly report: Q1 2026

Verastem Slides: Q1 2026

May 7, 2026, 4:30 PM EDT - 6 weeks ago

Verastem Slides: Q1 2026

Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates

May 7, 2026, 4:01 PM EDT - 6 weeks ago

Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates

Verastem announces launch of Reimagine Recurrent LGSOC campaign

2026-04-30T11:53:49.000Z - 7 weeks ago

Verastem announces launch of Reimagine Recurrent LGSOC campaign

Verastem Oncology Launches HCP and Patient Reimagine Campaign to Increase Awareness of AVMAPKI® FAKZYNJA® CO-PACK for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer

Apr 30, 2026, 7:30 AM EDT - 7 weeks ago

Verastem Oncology Launches HCP and Patient Reimagine Campaign to Increase Awareness of AVMAPKI® FAKZYNJA® CO-PACK for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer

Verastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026

Apr 23, 2026, 7:30 AM EDT - 2 months ago

Verastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026

Verastem announces two-year median follow-up data on AVMAPKI FAKZYNJA combo

2026-04-10T11:05:38.000Z - 2 months ago

Verastem announces two-year median follow-up data on AVMAPKI FAKZYNJA combo

Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Women's Cancers

Apr 10, 2026, 7:00 AM EDT - 2 months ago

Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Women's Cancers

Verastem Proxy statement: Proxy filing

Apr 9, 2026, 8:00 AM EDT - 2 months ago

Verastem Proxy statement: Proxy filing

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 2, 2026, 4:05 PM EDT - 2 months ago

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem assumed with a Buy at Jefferies

2026-03-30T13:00:48.000Z - 3 months ago

Verastem assumed with a Buy at Jefferies

Verastem management to meet with Cantor

2026-03-26T21:06:04.000Z - 3 months ago

Verastem management to meet with Cantor

Verastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026

Mar 17, 2026, 6:03 PM EDT - 3 months ago

Verastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026

Verastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI™ FAKZYNJA™ (avutometinib capsules; defactinib tablets) Combination Therapy at the Society of Gynecologic Oncology 2026 Annual Meeting on Women's Cancers

Mar 17, 2026, 4:44 PM EDT - 3 months ago

Verastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI™ FAKZYNJA™ (avutometinib capsules; defactinib tablets) Combination Therapy at the Society of Gynecologic Oncology 2026 Annual Meeting on Women's Cancers

Verastem assumed with a Buy at BTIG

2026-03-11T20:28:30.000Z - 3 months ago

Verastem assumed with a Buy at BTIG

Verastem price target raised to $18 from $16 at Alliance Global

2026-03-05T12:09:05.000Z - 3 months ago

Verastem price target raised to $18 from $16 at Alliance Global

Verastem Earnings Call Transcript: Q4 2025

Mar 4, 2026, 4:30 PM EST - 4 months ago

Verastem Earnings Call Transcript: Q4 2025

Verastem Earnings release: Q4 2025

Mar 4, 2026, 4:30 PM EST - 4 months ago

Verastem Earnings release: Q4 2025

Verastem Annual report: Q4 2025

Mar 4, 2026, 4:30 PM EST - 4 months ago

Verastem Annual report: Q4 2025

Verastem Slides: Q4 2025

Mar 4, 2026, 4:30 PM EST - 4 months ago

Verastem Slides: Q4 2025

Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business Updates

Mar 4, 2026, 4:01 PM EST - 4 months ago

Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business Updates

Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026

Feb 18, 2026, 7:30 AM EST - 4 months ago

Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026

Verastem Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 11, 2026, 2:00 PM EST - 4 months ago

Verastem Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Verastem Oncology Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK Pathway-Driven Cancers

Feb 4, 2026, 7:30 AM EST - 5 months ago

Verastem Oncology Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK Pathway-Driven Cancers

Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer

Dec 29, 2025, 4:01 PM EST - 6 months ago

Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer

Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth

Dec 15, 2025, 4:01 PM EST - 6 months ago

Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth

Verastem Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 10:25 AM EST - 7 months ago

Verastem Transcript: Evercore ISI 8th Annual HealthCONx Conference

Verastem Oncology to Present at the 8th Annual Evercore Healthcare Conference

Nov 25, 2025, 7:30 AM EST - 7 months ago

Verastem Oncology to Present at the 8th Annual Evercore Healthcare Conference

Verastem Transcript: Jefferies London Healthcare Conference 2025

Nov 19, 2025, 9:30 AM EST - 7 months ago

Verastem Transcript: Jefferies London Healthcare Conference 2025

Verastem Oncology Announces Pricing of $90 Million Public Offering of Common Stock and Pre-Funded Warrants

Nov 14, 2025, 12:41 AM EST - 7 months ago

Verastem Oncology Announces Pricing of $90 Million Public Offering of Common Stock and Pre-Funded Warrants

Verastem Oncology Announces Proposed Public Offering of Common Stock

Nov 13, 2025, 4:07 PM EST - 7 months ago

Verastem Oncology Announces Proposed Public Offering of Common Stock

Verastem Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 11, 2025, 1:00 PM EST - 8 months ago

Verastem Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Verastem Earnings Call Transcript: Q3 2025

Nov 4, 2025, 8:00 AM EST - 8 months ago

Verastem Earnings Call Transcript: Q3 2025

Verastem Quarterly report: Q3 2025

Nov 4, 2025, 8:00 AM EST - 8 months ago

Verastem Quarterly report: Q3 2025

Verastem Earnings release: Q3 2025

Nov 4, 2025, 8:00 AM EST - 8 months ago

Verastem Earnings release: Q3 2025

Verastem Oncology Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates

Nov 4, 2025, 7:30 AM EST - 8 months ago

Verastem Oncology Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates

Verastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with KRAS G12D Mutant Solid Tumors

Oct 23, 2025, 4:01 PM EDT - 8 months ago

Verastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with KRAS G12D Mutant Solid Tumors

Verastem Oncology to Report Third Quarter 2025 Financial Results on November 4, 2025

Oct 23, 2025, 7:30 AM EDT - 8 months ago

Verastem Oncology to Report Third Quarter 2025 Financial Results on November 4, 2025

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma

Oct 19, 2025, 4:15 AM EDT - 8 months ago

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma

Verastem Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 12:00 PM EDT - 10 months ago

Verastem Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Verastem Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 3:55 PM EDT - 10 months ago

Verastem Transcript: Cantor Global Healthcare Conference 2025

Verastem Oncology Announces Late-Breaking Abstract from Partner GenFleet Therapeutics' Study in China of GFH375 (VS-7375) in Advanced Non-Small Cell Lung Cancer at IASLC 2025 World Conference on Lung Cancer

Aug 13, 2025, 4:29 PM EDT - 11 months ago

Verastem Oncology Announces Late-Breaking Abstract from Partner GenFleet Therapeutics' Study in China of GFH375 (VS-7375) in Advanced Non-Small Cell Lung Cancer at IASLC 2025 World Conference on Lung Cancer

Verastem Registration statement: Registration Filing

Aug 12, 2025, 8:00 AM EDT - 11 months ago

Verastem Registration statement: Registration Filing

Verastem Registration statement: Registration Filing

Aug 8, 2025, 8:00 AM EDT - 11 months ago

Verastem Registration statement: Registration Filing

Verastem Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 11 months ago

Verastem Earnings Call Transcript: Q2 2025

Verastem Earnings release: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 11 months ago

Verastem Earnings release: Q2 2025

Verastem Quarterly report: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 11 months ago

Verastem Quarterly report: Q2 2025

Verastem Oncology Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates

Aug 7, 2025, 4:05 PM EDT - 11 months ago

Verastem Oncology Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates

Verastem Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025

Jul 29, 2025, 7:30 AM EDT - 11 months ago

Verastem Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025

Verastem Oncology Granted Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-mutated Locally Advanced or Metastatic Pancreatic Cancer

Jul 24, 2025, 7:30 AM EDT - 11 months ago

Verastem Oncology Granted Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-mutated Locally Advanced or Metastatic Pancreatic Cancer

Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology

Jul 11, 2025, 4:12 PM EDT - 1 year ago

Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology

Verastem Oncology Announces Nature Medicine Publication of the Results from the First-in-Human Phase 1 FRAME Study of Avutometinib in Combination with Defactinib in Solid Tumors, including Low-Grade Serious Ovarian Cancer

Jun 30, 2025, 4:02 PM EDT - 1 year ago

Verastem Oncology Announces Nature Medicine Publication of the Results from the First-in-Human Phase 1 FRAME Study of Avutometinib in Combination with Defactinib in Solid Tumors, including Low-Grade Serious Ovarian Cancer

Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors

Jun 24, 2025, 4:02 PM EDT - 1 year ago

Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors

Verastem Transcript: Jefferies Global Healthcare Conference 2025

Jun 4, 2025, 4:20 PM EDT - 1 year ago

Verastem Transcript: Jefferies Global Healthcare Conference 2025

Verastem Transcript: R&D Day 2025

Jun 2, 2025, 12:00 PM EDT - 1 year ago

Verastem Transcript: R&D Day 2025

Verastem Slides: FY 2025

Jun 2, 2025, 12:00 PM EDT - 1 year ago

Verastem Slides: FY 2025

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor

Jun 2, 2025, 9:40 AM EDT - 1 year ago

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor

Verastem Oncology to Present at the Jefferies Global Healthcare Conference

May 28, 2025, 7:30 AM EDT - 1 year ago

Verastem Oncology to Present at the Jefferies Global Healthcare Conference

Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma

May 22, 2025, 5:01 PM EDT - 1 year ago

Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma

Verastem Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 20, 2025, 3:35 PM EDT - 1 year ago

Verastem Transcript: RBC Capital Markets Global Healthcare Conference 2025

Verastem Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 20, 2025, 12:00 PM EDT - 1 year ago

Verastem Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment

May 20, 2025, 8:30 AM EDT - 1 year ago

Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment

TEM

Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates

May 13, 2025, 4:34 PM EDT - 1 year ago

Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates

Verastem Registration statement: Registration Filing

May 13, 2025, 8:00 AM EDT - 1 year ago

Verastem Registration statement: Registration Filing

Verastem Earnings release: Q1 2025

May 12, 2025, 6:00 PM EDT - 1 year ago

Verastem Earnings release: Q1 2025

Verastem Quarterly report: Q1 2025

May 12, 2025, 6:00 PM EDT - 1 year ago

Verastem Quarterly report: Q1 2025

FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer

May 8, 2025, 1:17 PM EDT - 1 year ago

FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer

U.S. FDA approves Verastem's cancer therapy

May 8, 2025, 12:23 PM EDT - 1 year ago

U.S. FDA approves Verastem's cancer therapy

Verastem Oncology Announces $75 million Private Placement

Apr 25, 2025, 9:00 AM EDT - 1 year ago

Verastem Oncology Announces $75 million Private Placement

Verastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid Tumors

Apr 23, 2025, 4:05 PM EDT - 1 year ago

Verastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid Tumors

Verastem Proxy statement: Proxy Filing

Apr 8, 2025, 8:00 AM EDT - 1 year ago

Verastem Proxy statement: Proxy Filing

Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025

Mar 25, 2025, 4:35 PM EDT - 1 year ago

Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025

Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates

Mar 20, 2025, 4:01 PM EDT - 1 year ago

Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates

Verastem Registration statement: Registration Filing

Mar 20, 2025, 8:00 AM EDT - 1 year ago

Verastem Registration statement: Registration Filing

Verastem Annual report: Q4 2024

Mar 19, 2025, 7:00 PM EDT - 1 year ago

Verastem Annual report: Q4 2024

Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer

Feb 20, 2025, 4:05 PM EST - 1 year ago

Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer

Verastem Transcript: Guggenheim SMID Cap Biotech Conference

Feb 5, 2025, 1:00 PM EST - 1 year ago

Verastem Transcript: Guggenheim SMID Cap Biotech Conference

Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference

Jan 29, 2025, 7:30 AM EST - 1 year ago

Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference

Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers

Jan 23, 2025, 7:30 AM EST - 1 year ago

Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers

Verastem Oncology Names Matthew E. Ros as Chief Operating Officer

Jan 15, 2025, 7:30 AM EST - 1 year ago

Verastem Oncology Names Matthew E. Ros as Chief Operating Officer

Always_neutral
Always_neutral Jun. 24 at 11:22 PM
$VSTM My brokerage recently sending any vstm order through a representative. This happened to few other stocks in the past and unfortunately they were in midst of an offering. I called them this morning. The rep just said they was a flag post on.this ticker but he doesn't know why. Anyway, my experience with this kind of situation always end up being an offering. Two recent examples were ANVS and ATOM. Anyway, it could be nothing but be careful with your bets. Sharing for FYI only. I will be glad if it helps someone. Good luck.
3 · Reply
Marketismanipulated2
Marketismanipulated2 Jun. 24 at 10:39 PM
$VSTM please announce a fucking buyout soon!
1 · Reply
ians
ians Jun. 24 at 10:25 PM
$VSTM There's the combo (VS-7375 + pan-RAS molecular glue) that could prevent tumor immune escape. 👍 Let's see early combo POC data ☘️💎 "Verastem and Erasca announce their intent to evaluate VS-7375 in combination with ERAS-0015, Erasca’s investigational pan-RAS molecular glue, in advanced KRAS G12D-mutant solid tumors" https://finance.yahoo.com/healthcare/articles/vs-7375-demonstrates-clinical-activity-200100930.html
1 · Reply
SagehenNed
SagehenNed Jun. 24 at 8:22 PM
$VSTM While the science may be decent, Dan and his executive team have created no value for shareholders. His financial management has been abysmal and the BOD has been asleep at the switch. It’s past time for an activist group to take over.
0 · Reply
sweddle
sweddle Jun. 24 at 8:20 PM
$VSTM
1 · Reply
Icabod63
Icabod63 Jun. 24 at 7:56 PM
$VSTM I am still bullish! Shame on me! My gut tells me an offering is coming in the $3.50 to $3.75 range and it has been leaked.
2 · Reply
Marketismanipulated2
Marketismanipulated2 Jun. 24 at 7:54 PM
$VSTM I don't remember hearing any bad news in that report, what the fuck am I missing? Corrupt motherfuckers!
0 · Reply
Crivit
Crivit Jun. 24 at 7:51 PM
$VSTM Clearly pure manipulation and preparation for a buyout.
1 · Reply
UnlikelyResult
UnlikelyResult Jun. 24 at 7:15 PM
$VSTM Down 7% in two hours on fewer than 100,000 shares. Not exactly a rush to the exits. But a great oppprtunity to fan panic by some
0 · Reply
Marketismanipulated2
Marketismanipulated2 Jun. 24 at 7:09 PM
$VSTM who the fuck would STILL be selling at these prices?
0 · Reply
boston_drew
boston_drew Jun. 24 at 7:05 PM
$VSTM I listen to some of the call - seems like the only hope is comment that they are talling with other companies so no specifics on the new partnership since they are shopping things around - can only hope they sell
0 · Reply
SagehenNed
SagehenNed Jun. 24 at 6:51 PM
$VSTM No bottom in sight, just endless selling.
0 · Reply
sweddle
sweddle Jun. 24 at 6:47 PM
$VSTM
0 · Reply
Marketismanipulated2
Marketismanipulated2 Jun. 24 at 6:24 PM
$VSTM sell the fucking thing already to highest bidder!
1 · Reply
Marketismanipulated2
Marketismanipulated2 Jun. 24 at 6:23 PM
$VSTM so great results and we tank! God I fucking hate useless, scourge if the earth parasitic shorts!
0 · Reply
PencilNeckGeek
PencilNeckGeek Jun. 24 at 6:16 PM
$VSTM Market seems to be certain that management is too greedy and too incompetent to seal the deal on any potential partnerships
1 · Reply
UnlikelyResult
UnlikelyResult Jun. 24 at 6:08 PM
$VSTM Bought
0 · Reply
Nodaz
Nodaz Jun. 24 at 6:07 PM
$VSTM any ideas here about a funding component involved with the possible collaboration with erasca?
0 · Reply
Sdcharger
Sdcharger Jun. 24 at 6:06 PM
$VSTM The finance team at VSTM is awful. I’ve never seen a company that consistently raises capital at the wrong time. And at the lowest prices. And they’re put themselves in another bind. A complete unforced error.
1 · Reply
CliffordCapital
CliffordCapital Jun. 24 at 5:34 PM
$VSTM $KYTX $PRME $WVE … all dragged up with XBI power.. once xbi goes Down all four fill fade hard. No I am not a bear I am actually long in all these but price action has been extremely poor on this xbi +10% move. Ridiculous
1 · Reply
SagehenNed
SagehenNed Jun. 24 at 5:19 PM
$VSTM Breaking down to new lows. The sellers/shorts just won't quit. Back to the 3s??
0 · Reply
CrozrX
CrozrX Jun. 24 at 3:56 PM
$VSTM VS-7375 infographic to sum it up. Trifecta!
3 · Reply